1. At a Glance – Small Hospital, Big Aspirations, Smaller Market Cap
₹7.95 crore. That’s the market cap. You’ve seen larger wedding budgets in Surat. Broach Lifecare Hospital Ltd, trading at ₹13.1, has managed to lose 31.6% in three months and 40.4% in six months, which is impressive consistency — just in the wrong direction.
Yet here’s the plot twist: despite being a newborn SME-listed hospital, it actually makes profits, runs debt-free, trades at 0.82x book value, and operates in cardiology — a segment where demand never sleeps, unlike midcap investors during concalls.
The latest Half-Yearly Results (H1 FY26) show sales of ₹2.60 crore, up 43.6% YoY, and PAT of ₹0.31 crore. Margins swing like an ECG graph, but profitability is still alive. ROCE sits at 9.45%, ROE at 7.28%, and promoter holding is a steady 63.76% with zero pledging.
So what do we have here? A 25-bed boutique cardiac hospital, operating under the Maple Hospitals brand, trying to punch above its weight in a sector dominated by corporate behemoths who spend more on branding than this company’s entire balance sheet.
Is this a hidden medical gem… or just a patient waiting in the OPD of the stock market? Let’s scrub in.
2. Introduction – Welcome to the ICU of SME Hospitals
Hospitals are supposed to save lives. SME hospital stocks? They mostly test investor patience.
Broach Lifecare Hospital Ltd, incorporated in 2023, is not pretending to be the next Apollo or Max Healthcare. No pan-India sprawl, no celebrity doctors, no glossy investor decks promising “asset-light scalability.” Instead, it runs a single boutique cardiac-focused hospital with 25 beds and a very specific ambition: fix hearts, not hype.
The company operates under the brand Maple Hospitals, offering 24/7 specialized cardiac care. From ECGs and TMTs to angiographies and pacemaker implantations — this place is less “general hospital” and more “cardiology nerd hub.”
Financially, the company is still in its awkward teenage phase. Revenues are growing, but profits fluctuate. Working capital days have ballooned to 154 days, debtor days to 70 days, and cash flows look like they need CPR.
Yet — and this is important — it is not burning money, not drowning in debt, and not doing random diversification into unrelated businesses (no cloud kitchens, no crypto advisory… yet).
So the real question is: can a tiny, focused cardiac hospital survive — and maybe even thrive — in an industry where scale usually eats focus for breakfast?
3. Business Model – WTF Do They Even Do? (In Simple Medical Terms)
Imagine explaining this to a smart investor who skipped biology classes.
Broach Lifecare runs a cardiac-specialty hospital. Not multi-specialty. Not cosmetic. Not wellness retreats with cucumber water. Just hearts. Human hearts.
Their services are split into four buckets:
Non-invasive cardiology — ECG, 2D Echo, Holter, TMT, ABPM. Basically diagnostics that tell you something is wrong.
Interventional cardiology — angiography, stents, PCI, primary PCI for heart attacks. This is where the real money is.
The hospital has 25 beds, including ICU and ICCU units. This is not about volume. This is about case-mix optimization — fewer patients, higher ticket size.
Revenue mix FY25 confirms this:
IPD income: ~78%
OPD: ~7%
Sale of consumables (Netts): ~13%
Everything else: rounding error
Translation? Patients come in sick, stay admitted, undergo procedures, and generate revenue. This is how specialty hospitals survive without footfall wars.
Now the risk: with one hospital, everything depends on occupancy, doctor availability, and local competition. One bad quarter, one senior cardiologist resigning, or one delayed insurance payment — and the P&L feels it immediately.
4. Financials Overview – Half-Yearly Results, Heartbeats Included
🔒 Result Type Locked: Half-Yearly Results (H1 FY26)
EPS annualisation rule applied: Latest EPS × 2
Financial Comparison Table (₹ in Crores, EPS in ₹)
